Preparation method for palbociclib
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 铜陵王燕堂生物科技有限公司
- Publication Date
- 2015-03-25
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the technical field of organic synthesis route design and preparation of raw materials and intermediates, and in particular relates to a preparation method of palbociclib, which may be used to treat breast cancer. Background technique
[0002] Palbociclib (Palbociclib) is a cell cycle-dependent kinase (CDK4 / 6) inhibitor developed by Pfizer, which was granted the "Breakthrough Therapy" qualification by the US FDA in April 2013. Due to its good clinical performance in Phase III, Pfizer submitted a marketing application to the US FDA in August 2014 and obtained priority review qualifications for estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative ( First-line treatment of HER2-) advanced breast cancer. The drug's successful research will provide another important option for patients with metastatic breast cancer. Because the medicine does not yet have a standard Chinese translation, the applica...